New Promise in the Treatment of MRSA

Some long-time readers of this blog will remember our son’s life-and-death struggle against MRSA (Methicillin-Resistant Staphylococcus Aureus) three years ago. A few others will know I also fought a similar infection last summer, and that Michael wrestled with a skin-level infection last fall. Though our son’s infection was much more serious and was treated through traditional western medical modalities for over a year, Michael and I battled ours at home using natural and homeopathic remedies and recovered much more quickly.

This article on today’s PhysOrg.com’s website sheds some light on an extremely hopeful discovery in the treatment of this strain of staph that is “spreading in epidemic proportions in hospital and community settings.”

Among the deadliest of all disease-causing organisms, Staph is the leading cause of human infections in the skin, soft tissues, bones, joints and bloodstream, and drug-resistant Staph infections are a growing threat. By federal estimates, more than 94,000 people develop serious MRSA infections and about 19,000 people die from MRSA in the U.S. every year. MRSA is believed to cause more deaths in the U.S. than HIV/AIDS.

Given that my son was almost one of those statistics, it would be good to see some actual research done to confirm whether more people actually do die from MRSA every year than from HIV/AIDS.

Among the brightest points for the new treatment is:

The new findings are particularly promising because BPH-652 already has been used (as a cholesterol-lowering agent) in human clinical trials, reducing the cost and time for development.

At a time when MRSA is encamped in hospitals and schools all over this country, real-world implementations of this discovery can’t come quickly enough.